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Abstract
Background: Pazopanib is an oral tyrosine kinase inhibitor registered for metastatic renal cell carcinoma and soft
tissue sarcoma. Liver toxicity is a common side effect for this class of agents. The current opinion is that in case of
severe liver toxicity pazopanib should be interrupted and restarted at a lower dose after returning to Common
Terminology Criteria for Adverse Events (CTCAE) grade 1. After recurrence of liver toxicity at the lower dose it is
advised to permanently stop pazopanib. We describe a patient with an YWHAE-FAM22 translocated endometrial
stromal sarcoma with a remarkable response to pazopanib despite recurrent liver toxicity.
Case Presentation: A 40 year old woman was diagnosed with metastatic YWHAE-FAM22 translocated endometrial
stromal sarcoma. She was treated successively with doxorubicin, megestrol acetate and anastrozole, before
pazopanib was initiated. Several dose interruptions and reductions were necessary due to liver toxicity, but
nevertheless she had a good partial response. Seven months after the start, pazopanib was permanently stopped
because of a bilateral pneumothorax. Nine months later it was reinitiated because of progression and was
continued for another 8 months until final disease progression.
Conclusion: In contrast to the current summary of product characteristics of pazopanib, the drug was successfully
continued despite recurrent liver toxicity, and no further liver function deterioration was found. This case suggests
that further dose reductions are good practice when liver toxicity limits treatment in responding patients.
Secondly, this patient with rare YWHAE-FAM22 translocated endometrial stromal sarcoma showed a remarkable
response to VEGFR/KIT inhibitor pazopanib. Recently, it was reported that this specific subtype of endometrial
stromal sarcoma overexpresses CD117, but has no KIT mutations.
This case illustrates that (a) pazopanib can be continued in patients with recurrent liver toxicity after dose
reductions under strict surveillance and that (b) pazopanib shows good efficacy in YWHAE-FAM22 translocated
endometrial stromal sarcoma.
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Background
The oral anti-angiogenic tyrosine kinase inhibitor (TKI)
pazopanib is a multi-target TKI [1]. Its main activity is
against vascular endothelial growth factor receptors
(VEGFR) 1, 2 and 3, platelet derived growth factor re-
ceptors (PDGFR) and KIT [1]. The phase III PALETTE
study showed an increase in the progression free survival
(PFS) from 1.6 months with placebo to 4.6 months with
pazopanib (Votrient®, GlaxoSmithKline) in patients with
metastatic soft tissue sarcoma [2, 3]. Pazopanib is also
effective in renal-cell carcinoma (RCC), with an increase
in PFS from 4.2 months with placebo to 9.2 months with
pazopanib [4]. Overall survival (OS) was also signifi-
cantly increased with pazopanib despite cross-over from
placebo treatment to pazopanib treatment [5].
Liver toxicity is a well-known side effect of pazopanib,
with an incidence in the PALETTE study of a grade ≥ 2
elevated alanine aminotransferase (ALAT) of 10% (pla-
cebo 3%) and aspartate aminotransferase (ASAT) of 8%
(placebo 2%) [2]. An increase in total bilirubin was not
seen in this study. In the RCC study, a National Cancer
Institute (NCI) Common Terminology Criteria for Ad-
verse Events (CTCAE) grade ≥ 3 increase in ALAT was
found in 12% (placebo 1%), ASAT 7% (< 1%) and total
bilirubin 3% (1%) [4]. Two patients in this RCC study
were assessed as having died due to abnormal hepatic
function. The current opinion is that physicians should
be careful prescribing pazopanib in patients with abnor-
mal ASAT, ALAT and total bilirubin levels and that
treatment should be discontinued at least temporarily
when grade 3 or more elevations occur during treat-
ment. In case of recurrence of liver function abnormal-
ities after restarting treatment pazopanib should be
stopped permanently [6].
Endometrial stromal neoplasms of the uterus are di-
vided into four categories based on the 2014 WHO classi-
fication, i.e. endometrial stromal nodule, low-grade
endometrial stromal sarcoma (ESS), high grade ESS and
undifferentiated uterine sarcoma [7, 8]. ESS is very rare,
representing 0.2% of all genital tract malignancies and the
patients are generally younger than in other uterine malig-
nancies. Low grade ESS is usually CD10 positive and Cyc-
lin D1 negative [9]. Fifty to 60 % of the ESS harbour
translocations involving JAZF1. Recently, it was found that
high grade ESS (negative for CD10, positive for Cyclin D1)
are characterised by a t(10;17)(q22;p13) translocation
resulting in a YWHAE-FAM22 (also known as YWHAE-
NUTM2A/B) gene fusion [10, 11]. It is suggested that
these tumours have a poor response to therapy compared
to the lower grade ESS, which has a 5 year disease specific
survival rate for FIGO stage III-IV of 50.3% [12]. Current
treatment for metastatic or locally advanced disease con-
sists of hormonal therapy and chemotherapy, i.e. doxo-
rubicin or ifosfamide monotherapy or gemcitabine/
docetaxel combination therapy [9]. Pazopanib is also reg-
istered for this soft tissue sarcoma subtype, but specific
studies are not available and will not be run because of the
rarity of this histologic subtype.
This case report describes a patient successfully
treated with pazopanib for an ESS developing abnormal
liver chemistry, which continued treatment with adapted
dosing of pazopanib under careful surveillance of liver
function. She had a remarkable response on pazopanib.
Case Presentation
A 40 year old female presented with a 4 months history
of recurrent right sided lower thoracic pain during
sports. Medical history consisted of a hysterectomy for
symptomatic uterine myomatosis four years previously,
after giving birth to her second child. This was a non-
radical non-oncological resection. The original pathology
report revealed a 15 cm low grade ESS. Now, four years
after the hysterectomy, a CT scan showed a large medi-
astinal mass with expansion in the upper abdomen and
compression of the left atrium and multiple lesions in
both lungs. A bronchoscopic biopsy showed cells similar
to the earlier diagnosed ESS. Treatment with six courses
of doxorubicin resulted in a very good partial response.
Maintenance therapy with megestrol acetate 160 mg was
started hoping to prolong the time to progression. Two
years later, an increase in size and number of the lung
metastases was observed, so megestrol acetate was
stopped and anastrozole 1 mg started. Further disease
progression was noticed 4 months later (Fig. 1a). Pazo-
panib 800 mg orally once daily was started in the named
patient program in collaboration with the Leiden Uni-
versity Medical Centre, one of the Dutch sarcoma refer-
ence centres. At the same time, pathology review was
performed, confirming the diagnosis of low grade ESS,
but also noticing a CyclinD1 positive and CD10 negative
higher grade component suggesting a YWHAE-FAM22
translocated ESS. (Fig. 2a-d) Fluorescent in situ hybrid-
isation confirmed the diagnosis. The tumour showed
high expression of KIT in the high grade component of
the tumour.
Six weeks after start of pazopanib 800 mg once daily
an increase in ALAT to > 10 times the upper limit of
normal (ULN) was observed. (Figure 3) Hepatitis ser-
ology, liver ultrasound and liver biopsy were not per-
formed because of the clear relationship of the increased
liver enzymes with the start of pazopanib. She had no
history of liver disease, no liver metastases and no liver
function abnormalities before start of pazopanib. During
the previous treatment with doxorubicin, y-glutamyl
transferase increased to 20× ULN and ALAT to 6×
ULN, no other liver function abnormalities occurred.
The CT scan showed a decrease in the sum of the largest
diameters of the target lesions of 23%. Pazopanib was
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put on hold immediately until the liver enzymes returned
to normal. (Figure 3) After six weeks without pazopanib
the CT scan showed a further decrease of the target le-
sions of 38% compared to baseline (19% compared to the
previous CT scan) indicating a partial response. Figure 1b)
At the time the liver toxicity had almost recovered, a re-
challenge with pazopanib 200 mg once daily was per-
formed, but after one week liver function abnormalities
recurred and pazopanib was stopped again. After liver
function recoverage, pazopanib 200 mg once every other
day was initiated, but again after 2 weeks liver enzymes in-
creased to > 3× ULN. Another week later pazopanib
200 mg every third day was given for 2 weeks, until a CT
scan showed progression (six months after the start of
pazopanib). She was still in very good clinical condition
and besides the remarkable inclination of liver enzymes at
the beginning of treatment and lesser rises thereafter she
had had little other toxicity with pazopanib. She consented
to another challenge with pazopanib 200 mg every day
under further strict surveillance of liver enzymes. The liver
enzymes remained < 3 times ULN, but 3 weeks later she
was admitted with a bilateral pneumothorax and pazopa-
nib was stopped. On the right side a pleurodesis was per-
formed and on the left side it was drained. Anastrozole
and leuproreline were prescribed, hoping to slow down
progression. Two months later, a CT scan again showed
progressive disease, and ifosfamide chemotherapy (5 g/m2
in a 24-h continuous infusion every 3 weeks) was initiated.
CT scans after 3 and 6 cycles showed stable disease. Dur-
ing ifosfamide treatment only a slight increase in y-
glutamyl transferase was noticed (increase to < 2× ULN).
Two months after the last ifosfamide administration,
radiological progression was observed again and pazopa-
nib 400 mg daily was prescribed again under strict weekly
surveillance of the liver enzymes. This dose was chosen
because patient had a pleural effusion due to the progres-
sion and thereby a lot of complaints. To be sure of a
therapeutic dose of pazopanib we started with 400 mg
daily. Two weeks after reinitiating pazopanib the pneumo-
thorax on the left side recurred and persisted. Pazopanib
was held for two weeks, but was then reinitiated after dis-
cussion of the risks with the patient. CT scans 6 weeks
and 3.5 months after the restart of pazopanib showed
stable disease. Pazopanib was stopped permanently
6 months after the restart because of progressive disease,
and she died 2 weeks later. In the second period of pazo-
panib treatment, no liver toxicity occurred. No differences
between co-medication were found between the first
period of pazopanib treatment and the second. A sum-
mary of the patients’ history is given in Fig. 4.
The DNA of the patient was analyzed for single nu-
cleotide polymorphisms (SNPs) in enzymes known to be
involved in the absorption, distribution, metabolism and
elimination of pazopanib [13]. The genes analyzed were
CYP3A4, CYP1A2, CYP2C8, ABCB1 and SLCO1B1. The
main metabolizing enzyme for pazopanib, CYP3A4 did
not have SNPs associated with a decreased metabolic
function. Two SNP variants in CYP1A2 (rs762551 and
rs2470890) and one in SLCO1B1 (rs4149057) were de-
tected, but no evidence exists that these polymorphisms
cause elevated levels of pazopanib. So, this analysis did
not result in the elucidation of a cause for the liver tox-
icity in this patient.
Discussion and conclusion
This case report has 2 new learning messages: we
present a patient with an ESS with a remarkable re-
sponse on pazopanib and we describe clinical manage-
ment of pazopanib induced recurrent liver toxicity.
Fig. 1 CT scans. Evaluation CT scans before start of pazopanib (a)
and 12 weeks after start of pazopanib (so 6 weeks on pazopanib
and 6 weeks off because of liver toxicity) (b) showing a shrinking
pulmonary metastasis measured by largest diameter at both times
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Liver function test abnormalities, mainly elevations in
ASAT and ALAT, are a common side effect of pazopanib
and more in general of TKIs [14]. The exact pathophysio-
logic mechanism is unknown. A distinctive class effect
seems to be unlikely, because pharmacologically different
TKIs are known to be hepatotoxic and the substances are
also very different chemical compounds. In a case series of
two patients with liver toxicity of pazopanib liver histology
showed mild active cholestatic hepatitis with inflammation
that predominantly involved portal tracts [15]. Recently, it
was reported that treatment with pazopanib in combination
with prednisolone in case of liver function abnormalities
prevented recurrence of liver function abnormalities in two
patients [16]. UDP-glucuronosyltransferase isoform 1A1
has been related to bilirubin elevations during pazopanib
treatment. These are probably patients with latent Gilbert
syndrome becoming evident due to the inhibitory effect of
pazopanib [14]. More recently, an association between
HLA-B*57:01 and pazopanib induced liver toxicity was
found [17]. Whether other germline genetic causes of pazo-
panib induced liver toxicity exist is unclear. The summary
of product characteristics (SmPC) of pazopanib contains
guidelines on handling liver toxicity [6]. If the elevation of
ASAT and ALAT between 3 and 8× ULN it is safe to con-
tinue pazopanib with strict control of ASAT and ALAT
until grade 1 toxicity. If ASAT and/or ALAT is more than
8× ULN then pazopanib should be stopped until recovery
till grade I or less and if reinitiated restart with pazopanib
Fig. 2 Histology. a: Normal HE slides of the lower grade component of ESS, showing spindled cells in a storiform pattern. b: HE slides of the high
grade component of ESS, showing round cells and open nuclei. c: Cyclin D1 expression of the lower grade component is weak and more
heterogeneous. d: Diffuse and strong Cyclin D1 expression in the high grade areas
Fig. 3 Course of pazopanib dose and laboratory parameters in time. ULN: upper limit of normal
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once daily 400 mg. It should be stopped permanently if
ASAT and/or ALAT rise again to > 3× ULN. Pazopanib
should also be stopped if ASAT and/or ALAT are elevated
> 3× ULN concurrently with a bilirubin elevated > 2× ULN.
In our case, despite these recommendations, pazopanib was
reintroduced at further reduced dose and no progressive
liver insufficiency developed. Ultimately this strategy
seemed to be effective until a dose reduction to 200 mg
once every second day. Another possible solution for tox-
icity management would be therapeutic drug monitoring,
which is possible for pazopanib with a dried blood spot
assay [18]. However, because the intrapatient variability of
pazopanib levels is high, a recent study could not show an
effect of therapeutic drug monitoring on the interpatient
variation [19]. A SNP analysis of genes for enzymes known
to be involved in the metabolism of pazopanib did not pro-
vide an explanation for elevated pazopanib levels or liver
toxicity in our patient. In case of further dose reductions
after reduction to once daily 400 mg, we suggest that pa-
tients should be monitored closely with once weekly liver
function testing.
The second message of this case report regards the pazo-
panib response related to the tumour type. When feasible
ESS is treated with radical surgery. Treatment of metastatic
or locally progressive ESS consists of endocrine therapy as
first line and when progressive on endocrine therapy chemo-
therapy. No specific data on the use of pazopanib in ESS is
available, but this case report shows that pazopanib induced
a partial response and prolonged PFS of 9 months which is
more than the median PFS in the PALETTE study. Although
in general ESS does not overexpress KIT, it was recently
shown that ESS harbouring the YWHAE-FAM22 fusion
gene frequently overexpress KIT (without a mutation in the
KIT oncogene) in the high grade component of the tumour,
as was the case in our patient [11, 20]. This could explain the
good response, in this rare histologic subtype, to pazopanib,
which is an inhibitor of VEGFRs, PDGFRs and KIT. Based
on these findings there may also be a potential role for ima-
tinib, which was already reported in two cases [21, 22]. Most
probably the evidence for treatments in ESS will be not bet-
ter than small case series due to the rarity of this disease.
The 3rd teaching point of this case report regarding
the occurrence and clinical development of a
pneumothorax during pazopanib treatment in (respond-
ing) patients with pleurally located metastatic lesions
was addressed in a previous case series [23].
In conclusion this case illustrates two important
new points:
– First, reversible severe liver toxicity with pazopanib
treatment is a known rare side effect of pazopanib
and low dose personalized rechallenge in responding
patients is a therapeutic option in experienced
hands. This low dose personalized rechallenge is in
conflict with the current SmPC of pazopanib and
patients should be closely monitored for liver
function abnormalities with for example weekly
testing of the liver functions.
– Second, pazopanib was found to result in a good
response in this patient with a YWHAE-FAM22A/B
translocated ESS which may be related to the KIT
overexpression in these tumours.
Abbreviations
ALAT: Alanine aminotransferase; ASAT: Aspartate aminotransferase;
CTCAE: Common Terminology Criteria for Adverse Events; ESS: Endometrial
stromal sarcoma; NCI: National Cancer Institute; OS: Overall survival;
PDGFR: Platelet derived growth factor receptors; PFS: Progression free
survival; RCC : Renal-cell carcinoma; SmPC: Summary of product
characteristics; SNP: Single nucleotide polymorphism; TKI: Tyrosine kinase
inhibitor; VEGFR: Vascular endothelial growth factor receptors
Acknowledgements
We would like to thank Marissa Nucci for reviewing the histological slides
and confirming the diagnosis and we would like to thank Djoeke de Wit for
helping us with the interpretation of the drug metabolism array.
Funding
No funding was received for this case report.
Availability of data and materials
The patients information used for this study is not publicly available due to
privacy regulations.
Authors’ contributions
AV and HG did the conception and design of the case report, did a review
of the literature and wrote the case report. FW provided the patient
information. JB and TB reviewed the histopathological specimens. FW, JB
and TB revised the manuscript. All authors read and approved the final
manuscript.
Ethics approval and consent to participate
Because no experimental treatment was used ethics approval is not
necessary. Patient consented to be part of the pazopanib compassionate use
Fig. 4 Timeline. Description of treatment in time
Verschoor et al. BMC Cancer  (2018) 18:92 Page 5 of 6
program and thereby consented for use of medical data for scientific
purposes. Consent to publish was given by her family, because the patient
has passed away. A copy of the written informed consent is available for
review by the Editor-in-Chief of this journal. Because no experimental treat-
ment was used, ethics approval is not necessary.
Consent for publication
Consent to publish was given by her family, because the patient has passed
away. A copy of the written informed consent is available for review by the
Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Medical Oncology, Leiden University Medical Centre,
Albinusdreef 2, Leiden, The Netherlands. 2Department of Internal Medicine,
Zuyderland Medical Centre, Henri Dunantstraat 5, Heerlen, The Netherlands.
3Department of Pathology, Leiden University Medical Centre, Albinusdreef 2,
Leiden, The Netherlands.
Received: 14 September 2016 Accepted: 16 January 2018
References
1. Harris PA, Boloor A, Cheung M, Kumar R, Crosby RM, Davis-Ward RG, Epperly
AH, Hinkle KW, Hunter RN 3rd, Johnson JH, et al. Discovery of 5-[[4-[(2,3-
dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-b
enzenesulfonamide (Pazopanib), a novel and potent vascular endothelial
growth factor receptor inhibitor. J Med Chem. 2008;51(15):4632–40.
2. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG,
Schoffski P, Aglietta M, Staddon AP, Beppu Y, et al. Pazopanib for metastatic
soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-
controlled phase 3 trial. Lancet. 2012;379(9829):1879–86.
3. Van Der Graaf WTA, Blay J-Y, Chawla SP, Kim D-W, Bui Nguyen B, Casali PG,
Schoffski P, Aglietta M, Staddon AP, Beppu Y, et al. PALETTE: final overall
survival (OS) data and predictive factors for OS of EORTC 62072/GSK
VEG110727, a randomized double-blind phase III trial of pazopanib versus
placebo in advanced soft tissue sarcoma (STS) patients. ASCO Meeting
Abstracts. 2012;30(15_suppl):10009.
4. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH,
Salman P, Gladkov OA, Kavina A, et al. Pazopanib in locally advanced or
metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin
Oncol. 2010;28(6):1061–8.
5. Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba
JJ, Gladkov OA, Lee E, Szczylik C, et al. A randomised, double-blind phase III
study of pazopanib in patients with advanced and/or metastatic renal cell
carcinoma: final overall survival results and safety update. European journal
of cancer (Oxford, England : 1990). 2013;49(6):1287–96.
6. SmPC pazopanib (Votrient) [http://www.ema.europa.eu/docs/en_GB/
document_library/EPAR_-_Product_Information/human/001141/
WC500094272.pdf].
7. Oliva E, Carcangiu ML, Carinelli SG, Ip P, Loening T, Longacre TA, Nucci MR,
Prat J, Zaloudek CJ. Mesenchymal tumours. In: Kurman RJ, Carcangiu ML,
Herrington CS, Young RH, editors. Pathology and genetics of Tumours of
female reproductive organs. 4th ed. Lyon: IARC; 2014. p. 141–5.
8. Ali RH, Rouzbahman M. Endometrial stromal tumours revisited: an update
based on the 2014 WHO classification. J Clin Pathol. 2015;68(5):325–32.
9. Rauh-Hain JA, del Carmen MG. Endometrial stromal sarcoma: a systematic
review. Obstet Gynecol. 2013;122(3):676–83.
10. Lee CH, Marino-Enriquez A, Ou W, Zhu M, Ali RH, Chiang S, Amant F, Gilks
CB, van de Rijn M, Oliva E, et al. The clinicopathologic features of YWHAE-
FAM22 endometrial stromal sarcomas: a histologically high-grade and
clinically aggressive tumor. Am J Surg Pathol. 2012;36(5):641–53.
11. Lee C-H, Hoang LN, Yip S, Reyes C, Marino-Enriquez A, Eilers G, Tao D,
Chiang S, Fletcher JA, Soslow RA, et al. Frequent expression of KIT in
endometrial stromal sarcoma with YWHAE genetic rearrangement. Mod
Pathol. 2014;27(5):751–7.
12. Chan JK, Kawar NM, Shin JY, Osann K, Lm C, Powell CB, Kapp DS.
Endometrial stromal sarcoma: a population-based analysis. Br J Cancer.
2008;99(8):1210–5.
13. van Geel RMJM, Beijnen JH, JHM S. Concise drug review: Pazopanib and
Axitinib. Oncologist. 2012;17(8):1081–9.
14. Shah R, Morganroth J, Shah D. Hepatotoxicity of tyrosine Kinase inhibitors:
clinical and regulatory perspectives. Drug Saf. 2013;36(7):491–503.
15. Klempner SJ, Choueiri TK, Yee E, Doyle LA, Schuppan D, Atkins MB. Severe
Pazopanib-induced Hepatotoxicity: clinical and Histologic course in two
patients. J Clin Oncol. 2012;30(27):e264–8.
16. Vlenterie M, van Erp NP, van der Graaf WTA. Promising management of
pazopanib-induced liver toxicity. Acta Oncol. 2015;54(7):1064–6.
17. Xu CF, Johnson T, Wang X, Carpenter C, Graves AP, Warren L, Xue Z, King
KS, Fraser DJ, Stinnett S, et al. HLA-B*57:01 confers susceptibility to
Pazopanib-associated liver injury in patients with cancer. Clin Cancer Res.
2016;22(6):1371–7.
18. de Wit D, den Hartigh J, Gelderblom H, Qian Y, den Hollander M, Verheul H,
Guchelaar HJ, van Erp NP. Dried blood spot analysis for therapeutic drug
monitoring of pazopanib. J Clin Pharmacol. 2015;55(12):1344–50.
19. de Wit D, van Erp NP, den Hartigh J, Wolterbeek R, den Hollander-van
Deursen M, Labots M, Guchelaar HJ, Verheul HM, Gelderblom H. Therapeutic
drug monitoring to individualize the dosing of pazopanib: a
pharmacokinetic feasibility study. Ther Drug Monit. 2015;37(3):331–8.
20. Sardinha R, Hernandez T, Fraile S, Tresserra F, Vidal A, Gomez MC, Astudillo
A, Hernandez N, Saenz de Santamaria J, Ordi J, et al. Endometrial stromal
tumors: immunohistochemical and molecular analysis of potential targets of
tyrosine kinase inhibitors. Clin Sarcoma Res. 2013;3(1):3.
21. Salvatierra A, Tarrats A, Gomez C, Sastre JM, Balaña C. A case of c-kit positive
high-grade stromal endometrial sarcoma responding to Imatinib Mesylate.
Gynecol Oncol. 2006;101(3):545–7.
22. Kalender M, Sevinc A, Yilmaz M, Ozsarac C, Camci C. Detection of complete
response to imatinib mesylate (Glivec®/Gleevec®) with 18F-FDG PET/CT for
low-grade endometrial stromal sarcoma. Cancer Chemother Pharmacol.
2009;63(3):555–9.
23. Verschoor AJ, Gelderblom H. Pneumothorax as adverse event in patients
with lung metastases of soft tissue sarcoma treated with pazopanib: a
single reference centre case series. Clin Sarcoma Res. 2014;4:14.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Verschoor et al. BMC Cancer  (2018) 18:92 Page 6 of 6
